Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-16 (of 16 Records) |
Query Trace: Tabidze I[original query] |
---|
Prior sexually transmitted infections and HIV in Mpox patients, Chicago, Illinois-(June 2022-March 2023
Faherty EAG , Holly T , Herrera K , Guidry T , Lyang J , Black S , Tabidze I . J Infect Dis 2024 229 S197-s202 HIV is associated with severe mpox. Sexually transmitted infections (STIs) could facilitate mpox transmission. We estimated HIV and STI frequency among patients with mpox and compared characteristics associated with mpox severity. Mpox cases during 1 June 2022 to 31 March 2023 were matched to Illinois HIV/AIDS surveillance data. Among 1124 patients with mpox, 489 (44%) had HIV and 786 (70%) had prior or concurrent STI; 307 (39%) had ≥3 STI episodes. More patients with mpox who were living with HIV were hospitalized than those without HIV (10.3% vs 4.1%, P < .001). STI screening visits are opportunities to vaccinate against mpox and provide HIV prophylaxis or treatment. |
Investigation of an mpox outbreak affecting many vaccinated persons in Chicago, IL-March 2023-June 2023
Faherty EAG , Holly T , Ogale YP , Spencer H , Becht AM , Crisler G , Wasz M , Stonehouse P , Barbian HJ , Zelinski C , Kittner A , Foulkes D , Anderson KW , Evans T , Nicolae L , Staton A , Hardnett C , Townsend MB , Carson WC , Panayampalli SS , Hutson CL , Gigante CM , Quilter LAS , Gorman S , Borah B , Black SR , Pacilli M , Kern D , Kerins J , McCollum AM , Rao AK , Tabidze I . Clin Infect Dis 2024 BACKGROUND: After months of few mpox cases, an increased number of cases were reported in Chicago during May 2023; predominantly among fully vaccinated patients. We investigated the outbreak scope, differences between vaccinated and unvaccinated patients, and hypotheses for monkeypox virus (MPXV) infection after vaccination. METHODS: We interviewed patients and reviewed medical records to assess demographic, behavioral, and clinical characteristics, mpox vaccine status, and vaccine administration routes. We evaluated serum antibody levels after infection and compared patient viral genomes with MPXV sequences in available databases. We discussed potential vaccine compromise with partners who manufactured, handled, and administered vaccine associated with breakthrough infections. RESULTS: During March 18-June 27, 2023, we identified 49 mpox cases; 57% of these mpox patients were fully vaccinated (FV). FV patients received both JYNNEOS doses subcutaneously (57%), intradermally (7%), or via heterologous administration (36%). FV patients had more median sex partners (3, IQR=1-4) versus not fully vaccinated (NFV) patients (1, IQR=1-2). Thirty-six of 37 sequenced specimens belonged to lineage B.1.20 of clade IIb MPXV, which did not demonstrate any amino acid changes relative to B.1, the predominant lineage from May 2022. Vaccinated patients demonstrated expected humoral antibody responses; none were hospitalized. No vaccine storage excursions were identified. Approximately 63% of people at risk for mpox in Chicago were FV during this period. CONCLUSIONS: Our investigation indicated cases were likely due to frequent behaviors associated with mpox transmission, even with relatively high vaccine effectiveness and vaccine coverage. Cases after vaccination might occur in similar populations. |
Notes from the field: Diagnosis of congenital syphilis and syphilis among females of reproductive age before and during the COVID-19 pandemic - Chicago, 2015-2022
Cejtin HE , Warren EF , Guidry T , Boss K , Becht A , Tabidze I . MMWR Morb Mortal Wkly Rep 2023 72 (47) 1288-1289 Syphilis is a bacterial infection that is of particular concern during pregnancy because of the risk for transplacental fetal infection. Pregnancies complicated by untreated syphilis are at increased risk for adverse outcomes, including stillbirth and long-term physical and cognitive sequelae in the affected infant. After implementation of enhanced efforts (1) by the Chicago Department of Public Health (CDPH) to eliminate congenital syphilis, including improvements to the surveillance and case management system, the number of Chicago congenital syphilis cases steadily decreased during 2015–2019, despite national increases in congenital syphilis and local increases in syphilis among females of reproductive age.* In 2020, with the emergence of the COVID-19 pandemic, the trend in Chicago abruptly shifted, and cases of congenital syphilis increased during the next 3 years. |
SARS-cov-2 reinfection risk in persons with HIV, Chicago, Illinois, USA, 2020-2022
Teran RA , Gagner A , Gretsch S , Lauritsen J , Galanto D , Walblay K , Ruestow P , Korban C , Pacilli M , Kern D , Black SR , Tabidze I . Emerg Infect Dis 2023 29 (11) 2257-2265 Understanding if persons with HIV (PWH) have a higher risk for SARS-CoV-2 reinfection may help tailor future COVID-19 public health guidance. To determine whether HIV infection was associated with increased risk for SARS-CoV-2 reinfection, we followed adult residents of Chicago, Illinois, USA, with SARS-CoV-2 longitudinally from their first reported infection through May 31, 2022. We matched SARS-CoV-2 laboratory data and COVID-19 vaccine administration data to Chicago's Enhanced HIV/AIDS Reporting System. Among 453,587 Chicago residents with SARS-CoV-2, a total of 5% experienced a SARS-CoV-2 reinfection, including 192/2,886 (7%) PWH and 23,642/450,701 (5%) persons without HIV. We observed higher SARS-CoV-2 reinfection incidence rates among PWH (66 [95% CI 57-77] cases/1,000 person-years) than PWOH (50 [95% CI 49-51] cases/1,000 person-years). PWH had a higher adjusted rate of SARS-CoV-2 reinfection (1.46, 95% CI 1.27-1.68) than those without HIV. PWH should follow the recommended COVID-19 vaccine schedule, including booster doses. |
Extragenital gonorrhoea, chlamydia, and HIV co-infection in people with mpox
Herrera K , Lyang J , Holly T , Faherty EA , Luc C , Korban C , Kern D , Tabidze I . Lancet Infect Dis 2023 23 (9) e334-e336 High prevalence of sexually transmitted infections, including gonorrhoea (28%), chlamydia (25%), syphilis (8%), and HIV (38%) co-infections have been reported in the 2022 mpox outbreak,1 which has disproportionately affected men who have sex with men and minoritised racial and ethnic groups.2 Although the outbreak has receded, a modelling analysis predicts that most jurisdictions in the USA could be at risk of resurgence without continued vaccination efforts.3 In previous mpox outbreaks, co-infection with HIV has been associated with poor mpox health outcomes.1, 4 Furthermore, among people with mpox in eight jurisdictions in the USA in 2022, those with HIV co-infection were more likely to report severe symptoms compared with those without HIV co-infection.1 Unprotected anal intercourse confers a significant risk for HIV acquisition as the rectal membrane is susceptible to infection due to its thin and friable nature.5 Previous gonorrhoea and chlamydia diagnoses are also established risk factors for HIV acquisition.6 These findings, along with clinical manifestations of mpox at rectal, genital, and oral sites warrant further investigation. This Correspondence aims to explore predictors, including gonorrhoea and chlamydia sites of infection in the previous 12 months of mpox diagnosis, and HIV co-infection among people with mpox in Chicago, USA. It is hypothesised that a previous or current rectal site of gonorrhoea or chlamydia infection will be associated with an increased prevalence of HIV and mpox co-infection. |
Notes from the field: Emergence of an mpox cluster primarily affecting persons previously vaccinated against mpox - Chicago, Illinois, March 18-June 12, 2023
Faherty EAG , Holly T , Ogale YP , Crisler G , Becht A , Kern D , Nicolae L , Spencer H , Wasz M , Kerins JL , Kittner A , Staton A , Hardnett C , Hutson C , Gigante CM , Quilter L , Kracalik I , Black S , McCollum AM , Rao AK , Tabidze I . MMWR Morb Mortal Wkly Rep 2023 72 (25) 696-698 During April 17–May 5, 2023, 13 monkeypox (mpox) cases were reported to the Chicago Department of Public Health (CDPH) after 2 months during which only a single case had been reported. The cluster was remarkable because it comprised more than 10 cases at a time when sporadic cases or small clusters (i.e., involving fewer than three cases) were being reported in the United States, and >69% of the persons in this cluster had received 2 doses of JYNNEOS or 1 dose of ACAM2000 vaccine.* Some cases among persons who received doses of JYNNEOS vaccine are expected to occur based on vaccine effectiveness data (1,2); however, the observed proportion of cases among persons who had received 2 doses of JYNNEOS or 1 dose of ACAM2000 in this cluster was unusual. This increase in cases before large summer events scheduled nationwide and in Chicago raised concerns about possible future case increases. | | On May 9, 2023, CDPH issued a health alert,† urging clinicians to remain vigilant for mpox cases and encouraging vaccination for persons at risk for mpox.§ CDPH and CDC launched an investigation to 1) determine the cluster’s scope and etiology by evaluating patients’ commonalities, JYNNEOS¶ vaccine cold-chain management, whole genome sequencing of clinical samples, and serologic immune response after infections, and to 2) identify important risk factors for mpox exposure to guide prevention efforts. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.** |
Assessing changes in insurance status and access to care among patients attending Chicago STI specialty clinics from 2013-2019
Korban C , Tabidze I , Broussard D , Cruz Y , Kern D , Mehta SD . Sex Transm Dis 2022 50 (3) 161-166 BACKGROUND: Public STI clinics are safety net providers for uninsured and underinsured individuals but are at risk for closure due to declining budgets and shifting priorities. This study sought to assess changes in insurance status and access to preventive care among public STI clinic patients following immediate and long-term implementation of the Affordable Care Act (ACA). MATERIALS AND METHODS: Patients receiving care in STI clinics administered by Chicago Department of Public Health were asked to complete an anonymous survey in 2013, 2014, and 2019. We estimated the prevalence rate ratio (PRR) of (1) being insured and (2) having access to preventive care over time, adjusted for age, race, and gender/sexual orientation, and employment status. RESULTS: Among 1,711 respondents, compared to 2013 patients, patients were 1.41 (adjusted PRR) times more likely to report being insured in 2014 (95% CI: 1.11-1.77), and 1.24 (aPRR) times more likely to report being insured in 2019 (95% CI: 0.99-1.55). After adjusting for other significant variables (age, sex and orientation, and insurance status), reported access to preventive care increased by 34% among respondents in 2019 as compared to 2013 (aPRR = 1.34). Unsurprisingly, being insured was associated with increased preventive care access (aPRR = 1.78). CONCLUSIONS: Even after implementation of the ACA, survey of public STI clinic patients in Chicago found a sizeable proportion of individuals without insurance, and many lacked access to preventive care, highlighting the continued need for these safety net clinics to provide STI care. |
HIV and sexually transmitted infections among persons with Monkeypox - eight U.S. Jurisdictions, May 17-July 22, 2022
Curran KG , Eberly K , Russell OO , Snyder RE , Phillips EK , Tang EC , Peters PJ , Sanchez MA , Hsu L , Cohen SE , Sey EK , Yin S , Foo C , Still W , Mangla A , Saafir-Callaway B , Barrineau-Vejjajiva L , Meza C , Burkhardt E , Smith ME , Murphy PA , Kelly NK , Spencer H , Tabidze I , Pacilli M , Swain CA , Bogucki K , DelBarba C , Rajulu DT , Dailey A , Ricaldi J , Mena LA , Daskalakis D , Bachmann LH , Brooks JT , Oster AM . MMWR Morb Mortal Wkly Rep 2022 71 (36) 1141-1147 High prevalences of HIV and other sexually transmitted infections (STIs) have been reported in the current global monkeypox outbreak, which has affected primarily gay, bisexual, and other men who have sex with men (MSM) (1-5). In previous monkeypox outbreaks in Nigeria, concurrent HIV infection was associated with poor monkeypox clinical outcomes (6,7). Monkeypox, HIV, and STI surveillance data from eight U.S. jurisdictions* were matched and analyzed to examine HIV and STI diagnoses among persons with monkeypox and assess differences in monkeypox clinical features according to HIV infection status. Among 1,969 persons with monkeypox during May 17-July 22, 2022, HIV prevalence was 38%, and 41% had received a diagnosis of one or more other reportable STIs in the preceding year. Among persons with monkeypox and diagnosed HIV infection, 94% had received HIV care in the preceding year, and 82% had an HIV viral load of <200 copies/mL, indicating HIV viral suppression. Compared with persons without HIV infection, a higher proportion of persons with HIV infection were hospitalized (8% versus 3%). Persons with HIV infection or STIs are disproportionately represented among persons with monkeypox. It is important that public health officials leverage systems for delivering HIV and STI care and prevention to reduce monkeypox incidence in this population. Consideration should be given to prioritizing persons with HIV infection and STIs for vaccination against monkeypox. HIV and STI screening and other recommended preventive care should be routinely offered to persons evaluated for monkeypox, with linkage to HIV care or HIV preexposure prophylaxis (PrEP) as appropriate. |
Antimicrobial susceptibility of urogenital and extragenital neisseria gonorrhoeae isolates among men who have sex with men - SURRG and eGISP, 2018-2019
Quilter LAS , St Cyr SB , Hong J , Asbel L , Bautista I , Carter B , Casimir Y , Denny M , Ervin M , Gomez R , Harvey A , Holderman JL , Johnson K , Kohn RP , Learner ER , Mauk K , Menza T , Mettenbrink C , Nettleton WD , Nicosia KR , Pham CD , Ried C , Schlanger K , Schneider A , Soge OO , Tabidze I , Taylor SN , Tilghman W , Toler C , Weinstock H , Torrone EA . Sex Transm Dis 2021 48 S111-S117 BACKGROUND: We investigated differences in gonococcal antimicrobial susceptibility by anatomic site among cisgender men who have sex with men (MSM) using specimens collected through CDC's enhanced Gonococcal Isolate Surveillance Project (eGISP) and Strengthening the U.S. Response to Resistant Gonorrhea (SURRG). METHODS: During January 1, 2018-December 31, 2019, 12 eGISP and 8 SURRG sites collected urogenital, pharyngeal, and rectal isolates from cisgender MSM in STD clinics. Gonococcal isolates were sent to regional laboratories for antimicrobial susceptibility testing by agar dilution. To account for correlated observations, linear mixed-effects models were used to calculate geometric mean minimum inhibitory concentrations (MICs) and mixed-effects logistic regression models were used to calculate the proportion of isolates with elevated or resistant MICs; comparisons were made across anatomic sites. RESULTS: Participating clinics collected 3,974 urethral, 1,553 rectal, and 1,049 pharyngeal isolates from 5,456 unique cisgender MSM. There were no significant differences in the geometric mean MICs for azithromycin, ciprofloxacin, penicillin, and tetracycline by anatomic site. For cefixime and ceftriaxone, geometric mean MICs for pharyngeal isolates were higher compared to anogenital isolates (p < 0.05). The proportion of isolates with elevated ceftriaxone MICs (≥0.125 μg/ml) at the pharynx (0.67%) was higher than at rectal (0.13%) and urethral (0.18%) sites (p < 0.05). CONCLUSIONS: Based on data collected from multi-jurisdictional sentinel surveillance projects, antimicrobial susceptibility patterns of N. gonorrhoeae isolates may differ among MSM at extragenital sites, particularly at the pharynx. Continued investigation into gonococcal susceptibility patterns by anatomic site may be an important strategy to monitor and detect the emergence of antimicrobial resistant gonorrhea over time. |
Chlamydia, gonorrhea, and HIV infection among transgender women and transgender men attending clinics that provide STD services in six US cities: Results from the STD Surveillance Network
Pitasi MA , Kerani RP , Kohn R , Murphy RD , Pathela P , Schumacher CM , Tabidze I , Llata E . Sex Transm Dis 2018 46 (2) 112-117 BACKGROUND: Transgender women and transgender men are disproportionately affected by HIV infection and may be vulnerable to other STDs, but the lack of surveillance data inclusive of gender identity hinders prevention and intervention strategies. METHODS: We analyzed data from 506 transgender women (1,045 total visits) and 120 transgender men (209 total visits) who attended 26 publicly funded clinics that provide STD services in six US cities during a 3.5-year observation period. We used clinical and laboratory data to examine the proportion of transgender women and transgender men who tested positive for urogenital and extragenital chlamydial or gonococcal infections and who self-reported or tested positive for HIV infection during the observation period. RESULTS: Of the transgender women tested, 13.1% tested positive for chlamydia and 12.6% tested positive for gonorrhea at one or more anatomic sites, and 14.2% were HIV-infected. Of transgender men tested, 7.7% and 10.5% tested positive for chlamydia and gonorrhea at one or more anatomic sites, and 8.3% were HIV-infected., Most transgender women (86.0% and 80.9%, respectively) and more than a quarter of transgender men (28.6% and 28.6%, respectively) with an extragenital chlamydial or gonococcal infection had a negative urogenital test at the same visit. CONCLUSIONS: Publicly funded clinics providing STD services are likely an important source of STD care for transgender persons. More data are needed to understand the most effective screening approaches for urogenital, rectal, and pharyngeal CT and GC infections in transgender populations. |
New human immunodeficiency virus diagnoses among men who have sex with men attending STD clinics, STD Surveillance Network, January 2010 to June 2013
Llata E , Braxton J , Asbel L , Kerani RP , Murphy R , Pugsley R , Pathela P , Schumacher C , Tabidze I , Weinstock HS . Sex Transm Dis 2018 45 (9) 577-582 OBJECTIVE: To estimate new HIV diagnosis rates among HIV negative MSM who are repeatedly tested for HIV in sexually transmitted disease (STD) clinics, and assess the impact of demographic and disease-specific characteristics that are associated with higher HIV diagnosis rates. STUDY DESIGN: Retrospective analysis using 2010-2013 data from the STD Surveillance Network (SSuN), a sentinel surveillance system comprised of health departments in 12 cities conducting sentinel surveillance in 40 STD clinics. We analyzed data from all MSM repeatedly (>/=2 times) tested for HIV, with an initial negative HIV test required for staggered cohort entry. Follow-up time was accrued from the date of the first negative HIV test to the most recent negative test or the first positive HIV test. STD diagnoses during the follow-up period were reviewed. We estimated HIV diagnoses rates (number of HIV diagnoses/total number of person-years at risk) by demographic and clinical characteristics with 95% confidence intervals (CI) using an inverse variance weighted random effects model, adjusting for heterogeneity between SSuN jurisdictions. RESULTS: Overall, 640 HIV diagnoses occurred among 14,824 individuals and 20,951.6 person-years (PY) of observation, for an adjusted incidence of HIV diagnosis of 3.0 per 100 PY (95% CI 2.6, 3.4). Rates varied across race/ethnicity groups with the highest rate among Blacks (4.7/100 PY; 95% CI 4.1-5.3) followed by Hispanics, Whites and persons of other races/ethnicities. MSM having a diagnosis of P&S syphilis on or after the first negative HIV test had a higher new HIV diagnosis rate (7.2/100 PY; 95% CI 5.8-9.0) compared to MSM who did not have a P&S syphilis diagnosis (2.8/100 PY; 95% CI 2.6-3.1). MSM who tested positive for rectal gonorrhea (6.3/100 PY; 95% CI 5.7-6.9) or rectal chlamydia (5.6/100 PY; 95% CI 4.6-6.6) had higher rates of new HIV diagnosis when compared to those with negative test results. CONCLUSIONS: MSM attending SSuN STD clinics have high rates of new HIV diagnoses, particularly those with a previous diagnosis of P&S syphilis, rectal chlamydia and/or gonorrhea. STD clinics continue to be important clinical setting for diagnosing HIV among MSM populations. |
Sexually transmitted infection clinics as safety net providers: exploring the role of categorical sexually transmitted infection clinics in an era of health care reform
Pathela P , Klingler EJ , Guerry SL , Bernstein KT , Kerani RP , Llata L , Mark HD , Tabidze I , Rietmeijer CA . Sex Transm Dis 2015 42 (5) 286-93 BACKGROUND: For many individuals, the implementation of the US Affordable Care Act will involve a transition from public to private health care venues for sexually transmitted infection (STI) care and prevention. To anticipate challenges primary care providers may face and to inform the future role of publicly funded STI clinics, it is useful to consider their current functions. METHODS: Data collected by 40 STI clinics that are a part of the Sexually Transmitted Disease Surveillance Network were used to describe patient demographic and behavioral characteristics, STI diagnoses, and laboratory testing data in 2010 and 2011. RESULTS: A total of 608,536 clinic visits were made by 363,607 unique patients. Most patients (61.9%) were male; 21.9% of men reported sex with men (MSM). Roughly half of patients were 20 to 29 years old (47.1%) and non-Hispanic black (56.2%). There were 212,765 STI diagnoses (mostly nonreportable) that required clinical examinations. A high volume of chlamydia, gonorrhea, and HIV testing was performed (>350,000 tests); the prevalence was 11.5% for chlamydia, 5.8% for gonorrhea, 0.9% for HIV, and varied greatly by sex and MSM status. Among MSM with chlamydia or gonorrhea, 40.1% (1811/4448) of chlamydial and 46.2% (3370/7300) of gonococcal infections were detected at extragenital sites. CONCLUSIONS: Sexually Transmitted Disease Surveillance Network clinics served populations with high STI rates. Given experience with diagnoses of both nonreportable and reportable STIs and extragenital chlamydia and gonorrhea testing, STI clinics comprise a critical specialty network in STI diagnosis, treatment, and prevention. |
Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men - STD Surveillance Network, United States, 2010-2012
Patton ME , Kidd S , Llata E , Stenger M , Braxton J , Asbel L , Bernstein K , Gratzer B , Jespersen M , Kerani R , Mettenbrink C , Mohamed M , Pathela P , Schumacher C , Stirland A , Stover J , Tabidze I , Kirkcaldy RD , Weinstock H . Clin Infect Dis 2014 58 (11) 1564-70 BACKGROUND: Gonorrhea (GC) and chlamydia (CT) are the most commonly reported notifiable diseases in the U.S. CDC recommends that men who have sex with men (MSM) be screened for urogenital GC/CT, rectal GC/CT, and pharyngeal GC. We describe extragenital GC/CT testing and positivity among MSM attending sexually transmitted disease (STD) clinics. METHODS: The STD Surveillance Network collects patient data from 42 STD clinics. We assessed the proportion of MSM attending these clinics during July 2011-June 2012 who were tested and positive for extragenital GC/CT at their most recent visit or in the preceding 12 months and the number of extragenital infections that would have remained undetected with urethral screening alone. RESULTS: Of 21,994 MSM, 83.9% were tested for urogenital GC, 65.9% for pharyngeal GC, 50.4% for rectal GC, 81.4% for urogenital CT, 31.7% for pharyngeal CT, and 45.9% for rectal CT. Of MSM tested, 11.1% tested positive for urogenital GC, 7.9% for pharyngeal GC, 10.2% for rectal GC, 8.4% for urogenital CT, 2.9% for pharyngeal CT, and 14.1% for rectal CT. Over 70% of extragenital GC infections and 85% of extragenital CT infections were associated with negative urethral tests at the same visit and would not have been detected with urethral screening alone. CONCLUSIONS: Extragenital GC/CT was common among MSM attending STD clinics, but many MSM were not tested. Most extragenital infections would not have been identified, and likely would have remained untreated, with urethral screening alone. Efforts are needed to facilitate implementation of extragenital GC/CT screening recommendations for MSM. |
Prevalence of genital warts among sexually transmitted disease clinic patients - Sexually Transmitted Disease Surveillance Network, United States, January 2010 to December 2011
Llata E , Stenger M , Bernstein K , Guerry S , Kerani R , Pugsley R , Pathela P , Tabidze I , Weinstock H . Sex Transm Dis 2014 41 (2) 89-93 BACKGROUND: A quadrivalent vaccine that prevents genital warts (GWs) has been recommended by the Advisory Committee on Immunization Practices for women since 2007 and for men since 2011. National estimates of GW burden in sexually transmitted disease (STD) clinic settings are useful to provide a baseline assessment to monitor and evaluate reductions in GW and serve as an important early measure of human papillomavirus (HPV) vaccine impact in this population. METHODS: Genital wart prevalence among STD clinic patients from January 2010 to December 2011 was determined from a cross-sectional analysis of all patients attending STD clinics in the STD Surveillance Network (SSuN). We conducted bivariate analyses for women, men who have sex with women (MSW), and men who have sex with men (MSM) separately, using chi statistics for the association between GW diagnosis and demographic, behavioral, and clinical characteristics. RESULTS: Among 241,630 STD clinic patients, 13,063 (5.4%) had GWs. Wide regional differences were observed across SSuN sites. The prevalence of GW was as follows: 7.5% among MSW (range by SSuN site, 3.9-15.2), 7.5% among MSM (range, 3.3-20.6), and 2.4% among women (range, 1.2-5.4). The highest rate was among 25- to 29-year-old MSW (9.8%). Non-Hispanic black women and MSW had a lower prevalence of GWs than did women and MSW in other racial/ethnic groups. CONCLUSIONS: There is a significant burden of GW in STD clinic populations, most notably in men. Given the opportunity for prevention with a quadrivalent HPV vaccine, STD clinics may be an ideal setting for monitoring trends in GW prevalence among men (MSW and MSM). However, given the observed low GW prevalence among female STD clinic patients, STD clinics may not provide an appropriate setting to monitor the impact of HPV vaccine among women. |
HIV testing among patients infected with Neisseria gonorrhoeae: STD Surveillance Network, United States, 2009-2010
Bradley H , Asbel L , Bernstein K , Mattson M , Pathela P , Mohamed M , Samuel MC , Schwebke J , Stenger M , Tabidze I , Zenilman J , Dowell D , Weinstock H . AIDS Behav 2012 17 (3) 1205-10 We used data from the STD Surveillance Network to estimate HIV testing among patients being tested or treated for gonorrhea. Of 1,845 gonorrhea-infected patients identified through nationally notifiable disease data, only 51% were tested for HIV when they were tested or treated for gonorrhea. Among the 10 geographic sites in this analysis, the percentage of patients tested for HIV ranged from 22-63% for men and 20-79% for women. Nearly 33% of the un-tested patients had never been previously HIV-tested. STD clinic patients were more likely to be HIV-tested than those in other practice settings. |
HPV vaccine implementation in STD clinics - STD Surveillance Network
Meites E , Llata E , Hariri S , Zenilman J , Longfellow L , Schwebke J , Tabidze I , Mettenbrink C , Jenkins H , Guerry S , Pathela P , Asbel L , Stover JA , Bernstein K , Kerani RP , Dunne EF , Markowitz LE . Sex Transm Dis 2012 39 (1) 32-34 We surveyed selected public sexually transmitted disease clinics in the United States regarding human papillomavirus vaccine availability, target populations, funding sources, and barriers. Although nearly all had experience offering other vaccines, only 7 of 42 clinics (17%) offered human papillomavirus vaccine. Vaccine cost, staff time, and follow-up issues were commonly reported barriers. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure